LeMaitre Vascular Inc. shares declined to a 52-week low of $78.64 on Friday, following a second-quarter earnings report that fell short of Wall Street expectations.
The medical device manufacturer reported adjusted earnings of $0.74 per share on revenue of $70.4 million, missing analyst projections of $0.81 per share and $71.47 million, respectively. Despite the miss, the company posted year-over-year growth in both profit and sales for the quarter.
Shares traded at $78.77, roughly 1% above the 52-week low and down 16.96% over the past year. Analysts noted the company’s strong fundamentals, including a PEG ratio of 0.71, which suggests value relative to growth. InvestingPro’s analysis also labeled LeMaitre Vascular as undervalued compared to its fair value.
The earnings miss prompted the company to revise its full-year growth outlook downward, signaling a more cautious stance amid broader market pressures. The stock’s decline follows a broader trend in the medical device sector, where companies have faced scrutiny over growth sustainability and cost management.
LeMaitre Vascular, which specializes in vascular repair and preservation devices, has maintained a strong financial health score despite recent volatility. The company’s performance contrasts with historical AI-picked strategy benchmarks, such as Siemens Energy’s 231.5% gain and Sandisk’s 189% increase over comparable periods.
